<DOC>
	<DOCNO>NCT00048672</DOCNO>
	<brief_summary>The goal clinical research study see imatinib mesylate ( Gleevec , STI571 ) improve CML chronic phase . Objectives : Primary Objective : To increase proportion patient achieve complete cytogenetic response patient Ph-positive early chronic phase CML use initial Gleevec therapy . Secondary Objective : To evaluate duration cytogenetic response , duration hematologic response survival .</brief_summary>
	<brief_title>Therapy Early Chronic Phase CML With Gleevec</brief_title>
	<detailed_description>Before treatment start , patient physical exam include medical history documentation disease , blood test , bone marrow study . The bone marrow remove large needle . Patients study take 400 mg imatinib daily ( morning evening ) . If side effect , dose may lower . If response good , dose imatinib mesylate increase 800 mg daily ( 400 mg morning 400 mg even ) may decrease 300 mg daily base drug tolerate . Imatinib mesylate take large glass water . Bottles contain tablet give patient every 6 month . Unused supply must return end study . After complete 3 12 month therapy , response imatinib mesylate evaluate . If response good , treatment imatinib mesylate alone continue . Treatment may continue 20 year , long judged best control leukemia . Update : June 2010 : Blood test recommend 2 time per year . Your doctor discus often blood test . Bone marrow do doctor think necessary check disease . You must return MD Anderson least every year . You may need bone marrow test every visit , blood drawn measure amount disease . If leukemia find 2 year longer blood test call PCR do measure amount disease , doctor may talk stop treatment imatinib . If doctor decide stop therapy , blood test PCR do every 3 6 month . You need return MD Anderson blood test do . You may blood take local doctor mail MD Anderson . If leukemia find PCR blood test , doctor may recommend restart treatment imatinib . You may decide stay treatment imatinib even PCR blood test show sign leukemia 2 year longer . This investigational study . Imatinib mesylate approve CML . A total 50 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Diagnosis Philadelphia chromosome ( Ph ) positive breakpoint cluster region ( bcr ) positive CML early chronic ( diagnosis &lt; 12 month ) . 2 . Age 15 year 3 . Adequate renal , hepatic , cardiac performance status ( ECOG 02 ) psychiatric disability ( psychosis ) 4 . Signed informed consent 1 . Grade 34 cardiac 2 . Psychiatric problem 3 . Pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Early Chronic Phase Chronic Myelogenous Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Gleevec</keyword>
	<keyword>STI571</keyword>
	<keyword>Imatinib mesylate</keyword>
</DOC>